【摘 要】
:
Ethnopharmacological relevance: Shenmai injection (SMI) is a traditional Chinese herbal medicine extracted from Panax ginseng (Panax ginseng C.A.Mey,steamed and dry) and Ophiopogon japonicus (Ophiopog
【机 构】
:
The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China
论文部分内容阅读
Ethnopharmacological relevance: Shenmai injection (SMI) is a traditional Chinese herbal medicine extracted from Panax ginseng (Panax ginseng C.A.Mey,steamed and dry) and Ophiopogon japonicus (Ophiopogon japonicus (L.f.) Ker-Gawl,root).It has been widely used for the treatment of chronic heart failure (CHF) in China However,the evidence supporting its effects remains unclear due to lack of high quality trials.The aim of this study was to investigate the efficacy and safety of SMI in CHF patients with coronary artery disease (CAD).Materials and methods: This double-blind,multicenter study randomized 240 eligible patients equally to receive SMI or placebo (100 ml/day) in addition to standard medicines for the treatment of CHF.The primary endpoint was the New York Heart Association (NYHA) functional classification.The secondary endpoints were 6-min walking distance (6MWD),short-form 36 (SF-36) hearth survey score,traditional Chinese medicines (TCM) syndrome score,left ventricular ejection fractions (LVEF) and B-type natriuretic peptide (BNP) level.Results: During treatment of 1 week,the NYHA functional classification was gradually improved in both groups,but the SMI group demonstrated a significantly greater improvement compared with the placebo group (p =0.001).Moreover,the improvement in patients received SMI was superior to those in control group with respect to 6MWD,SF-36 score and TCM syndrome score.Treatment with SMI within 1 week was well tolerated with no apparent safety concerns.Conclusions: The integrative treatment with standard medicines plus SMI can further improve NYHA functional classification for patients with CHF and CAD.Therefore,SMI could be recommended in the combination therapy for CHF accompanied with CAD.
其他文献
目的:观察心血管护理门诊对出院后的冠心病患者急性心脑血管病事件发生率的影响.方法:将心血管内科出院后的100例冠心病患者随机分为观察组(护理门诊组)和对照组(无护理门诊组),比较半年内急性心脑血管病事件的发生率和再住院率.结果:观察组的急性心脑血管病事件的发生率和再住院率明显低于对照组(P<0.05),具有统计学差异.结论:冠心病患者出院后有计划的护理门诊随访,可以提高患者用药依从性,降低急性心脑
冠状动脉介入治疗(percutaneous coronary intervention,PCI)自中国开展以来得到迅猛发展,尤其是迈入药物洗脱支架时代的今日.据2012年长城国际心血管病会议报告,2000年中国内地完成2万例PCI手术,2011年已经超过40万.但OAT和COURAGE试验结果告诉,介入治疗并不能解决所有的临床问题,更为重要的是,尚有一些与PCI手术相关的问题需要解决,如无复流、缺
为系统评价健身气功八段锦对原发性高血压患者收缩压和舒张压的干预效果,通过检索Pubmed、EMbase、Cochrane library、CNKI、CBM、VIP、WF等数据库收集文献,整理提取文献信息并用RevMan5.2软件对治疗后收缩压(SBP)和舒张压(DBP)的数值进行Meta分析.结果:显示,八段锦干预组与对照组之间存在显著差异.结论:八段锦干预组对比常规治疗组在血压控制方面有一定的作
目的:探讨广东省名中医黄衍寿治疗眩晕的用药规律.方法:收集广州中医药大学第一附属医院2015年8月至2016年6月黄衍寿教授门诊治疗眩晕病例的处方,应用“中医传承辅助平台”软件,采用数据挖掘方法,分析黄衍寿教授治疗眩晕的用药规律.结果:纳入病例150例,处方150首,药物共计118味.处方中高频证型为肝肾不足(54)、瘀血内阻(41);频次最高的前4位药物为川芎(107)、丹参(96)、天麻(92
目的:探讨心灵丸在治疗冠心病经皮冠状动脉介入治疗术(percutaneoustransluminalcoronaryintervention,PCI)后合并焦虑患者的临床效果.方法:80例接受冠心病PCI术治疗成功患者,按随机数字表法分为对照组与观察组,两组各40例.对照组采用常规冠心病二级预防药物及心理疏导,治疗组在常规西药治疗基础上联合心灵丸治疗.结果:治疗组患者在心率及心肌耗氧量方面较对照组
目的:观察半夏白术天麻汤联合缬沙坦治疗肥胖型高血压的临床疗效.方法:将80例肥胖型轻中度高血压患者按照完全随机化法分为治疗组和对照组各40例,两组均予同一公司生产的缬沙坦(80mg QD),治疗组在对照组基础上配合半夏白术天麻汤.治疗12周后分别观察两组患者治疗前后中医症候积分、血压(SBP/DBP)、体重指数(Body mass index,BMI)、甘油三酯(Triglyceride,TG)、
目的:分析合并2型糖尿病的痰瘀互结型高血压病患者的血栓弹力图(thromboelastography,TEG)检测结果,从而评价其血栓风险,以指导临床治疗.方法:选取符合标准的痰瘀互结型高血压病患者180例,按照是否合并2型糖尿病分为糖尿病组(n=86)和非糖尿病组(n=94),测定所有对象的TEG各项参数[R值、K值、Angle(A角)、Ma值],观察比较上述指标在两组间的差异.结果:糖尿病组与
本例患者以发作性心悸、胸闷、乏力、口唇苍白、汗出为主要症状,多次监测患者发作时心率及血压均在正常范围,完善了与上述症状相关的常见的发作性疾病的多项检查,排除了心律失常、冠心病、癫痈、低血糖、甲亢、焦虑症、抑郁症、更年期综合征等疾病。最后根据发作时血压、心率虽然在正常范围,但较未发作时有所升高,考虑是否存在发作性儿茶酚胺分泌增多的疾病——嗜铬细胞瘤,根据这一思路,完善了相关影像和内分泌相关的检查,影
目的:观察活血潜阳方对肥胖高血压患者体重、BMI、血压、中医症状的改善作用.方法:将50例伴左室重构的肥胖高血压患者随机分为对照组及治疗组,其中对照组25例,治疗组23例.治疗组在西药治疗基础上加载活血潜阳方进行干预,疗程3个月.干预前后采集患者一般资料、诊室血压,中医证候积分、糖脂代谢、心脏超声等指标进行比较.结果:①治疗组患者体重、腰围、BMI均较治疗前显著下降(P<0.05);对照组治疗前后
目的:观察中成药补肾益心片对高血压大鼠(SHR)血压的影响和对其勃起功能的干预作用,NOS、NO及Ang(1-7)的干预作用.探讨自发性高血压大鼠(SHR)勃起功能的改变及其发病机制.探讨自发性高血压大鼠(SHR)勃起功能的改变及其发病机理.方法:原发高血压雄性大鼠分为三组,补肾益心片组、缬沙坦组、模型对照组.分别予以补肾益心片、缬沙坦、生理盐水灌胃.治疗四周后,检测阴茎海绵体组织内NOS、NO浓